Anticoagulation in Patients With Venous Thromboembolism and Cancer

VICTORIE (VTE IN CANCER - TREATMENT, OUTCOMES AND RESOURCE USE IN EUROPE)

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Inclusion Criteria:

• A VTE diagnosis
• Active cancer or history of cancer
• Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
• Age ≥ 18 years at the date of index VTE (Venous thromboembolic)

Exclusion Criteria:

• Prior VTE diagnosis
• Diagnosis of prior atrial fibrillation
• Inferior Vena Cava (IVC) filter
• Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed.
• Pregnancy
• More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date.
• Patients with less than one day of follow up